cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Biopharmaceutical firm develops anticancer immunotherapy based on IVIg
December 14th, 2004
GammaCan International, Inc., (GCAN), a developer of immunotherapies for cancer and other serious conditions, announced that it may have discovered a new weapon in the fight to keep melanoma, carcinoma, sarcoma, lymphoma, and other deadly cancers from spreading or returning in patients. The patented therapy, based on Intravenous Immunoglobulin (IVIg), is a concentrated form of disease-fighting antibodies naturally occurring in human blood. Based on the company's preclinical results and year-long clinical experience with IVIg, the company believes that this new therapy may open an exciting new treatment option that is safe, effective, and minimally toxic. ...
Source: cancer weekly (2004-12-14)
|
